Cardiology Meetings in COVID-19: What’s worked so far? What hasn’t? Roxana Mehran hears from Ron Blankstein and Asif Qasim.

Digoxin improved some measures of quality of life at 12 months and was associated with greater reductions in NYHA class and NT-proBNP. Digoxin was also associated with fewer adverse events compared with beta-blockers.